Valuation: Kymera Therapeutics, Inc.

Market Cap 10.19B 9.12B 8.42B 7.62B 14.24B 970B 14.47B 100B 40.06B 508B 38.23B 37.42B 1,608B P/E 2026 *
-31.6x
P/E 2027 * -24.2x
Enterprise Value 8.88B 7.96B 7.34B 6.64B 12.42B 846B 12.62B 87.59B 34.94B 443B 33.34B 32.63B 1,402B EV / Sales 2026 *
84.8x
EV / Sales 2027 * 224x
Free-Float
97.88%
Yield 2026 *
-
Yield 2027 * -
1 day+0.07%
1 week+10.60%
Current month+9.67%
1 month+10.94%
3 months+16.48%
6 months+50.41%
Current year+57.56%
1 week 110.31
Extreme 110.312
127.74
1 month 101.74
Extreme 101.745
127.74
Current year 66.2
Extreme 66.205
130.05
1 year 55.66
Extreme 55.66
130.05
3 years 9.6
Extreme 9.6
130.05
5 years 9.6
Extreme 9.6
130.05
10 years 9.6
Extreme 9.6
130.05
Manager TitleAgeSince
Chief Executive Officer 47 2019-10-31
Director of Finance/CFO 56 2019-07-14
Chief Tech/Sci/R&D Officer - 2026-07-26
Director TitleAgeSince
Chairman 52 2017-07-31
Director/Board Member 47 2019-10-31
Director/Board Member 37 2020-02-29
Date Insider Type Main position Quantity % Market Cap. Importance
10/1/26 Exercice

Founder

90,000 0.1082%
9/4/26 Sell

General Counsel

-6,371 0.0077%
7/27/26 Free

Chief Technology Officer

114,000 0.1386%
Change 5-day change 1-year change 3-year change Capi.($)
+0.07%+10.60%+104.23%+1,017.59% 10.19B
+0.34%+1.12%+34.75%+61.06% 64.14B
+0.98%+2.26%+12.91%+82.98% 55.53B
+1.75%+2.76%+12.38%+103.69% 53.03B
-1.43%-1.17%+26.27%+52.86% 45.99B
-0.48%-2.80%+18.01%+117.99% 42.45B
+0.82%+1.37%+227.94%+922.41% 40.45B
-0.26%-4.20%+10.86%+45.18% 32.25B
-2.07%+44.58%+102.84%+88.74% 34.47B
-2.72%-8.79%+22.58%-5.63% 24.23B
Average -0.30%+4.32%+57.28%+248.69% 40.27B
Weighted average by Cap. -0.07%+3.27%+50.41%+182.55%

Financials

2026 *2027 *
Net sales 105M 93.84M 86.57M 78.34M 146M 9.98B 149M 1.03B 412M 5.22B 393M 385M 16.54B 40.65M 36.41M 33.59M 30.4M 56.84M 3.87B 57.76M 401M 160M 2.03B 153M 149M 6.42B
Net income -382M -342M -316M -286M -535M -36.41B -543M -3.77B -1.5B -19.05B -1.43B -1.4B -60.35B -516M -462M -426M -386M -721M -49.1B -733M -5.08B -2.03B -25.7B -1.94B -1.89B -81.39B
Net Debt -1.3B -1.17B -1.08B -974M -1.82B -124B -1.85B -12.84B -5.12B -64.9B -4.89B -4.78B -206B -1.09B -975M -899M -814M -1.52B -104B -1.55B -10.73B -4.28B -54.23B -4.08B -4B -172B
Projected Income Statement - Annual - Kymera Therapeutics, Inc.
Logo Kymera Therapeutics, Inc.
Kymera Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system with a primary focus on immunology. The Company's targeted protein degradation (TPD) platform, which is a small molecule therapeutic modality that engages the body’s natural cellular recycling system to selectively eliminate disease-causing proteins. Its immunology programs target STAT6, IRF5 and IRAK4, each of which addresses targets within validated pathways, providing the opportunity to treat a broad range of diseases. It is developing KT-621 as part of its STAT6 program, which is being evaluated in a Phase I clinical trial in healthy volunteers. It is developing KT-579, which is an investigational, first-in-class, oral IRF5, degrader being developed for the treatment of rheumatic and autoimmune diseases.
Employees
273
Date Price Change Volume
26-10-29 US$122.60 +0.07% 1,045,357
26-10-28 US$122.51 +4.20% 768,151
26-10-27 US$117.57 +2.38% 828,869
26-10-26 US$114.84 +3.68% 438,576
26-10-23 US$110.76 -0.08% 517,064
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
MarketScreener Ratings - Kymera Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
122.60USD
Average target price
139.83USD
Spread / Average Target
+14.05%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Kymera Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. KYMR Stock